<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276523</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000441020</org_study_id>
    <secondary_id>MDA-ID-01450</secondary_id>
    <secondary_id>ID01-450</secondary_id>
    <nct_id>NCT00276523</nct_id>
    <nct_alias>NCT00078416</nct_alias>
  </id_info>
  <brief_title>PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>A Randomized Phase II Study of SCH 54031 in Surgically Resectable Squamous Cell Tumors of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: SCH 54031 (PEG-interferon alfa-2b) may interfere with the growth of tumor cells&#xD;
      and slow the growth of head and neck cancer. It may also stop the growth of head and neck&#xD;
      cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b before surgery may&#xD;
      make the tumor smaller and reduce the amount of normal tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well different doses of&#xD;
      PEG-interferon alfa-2b work in treating patients with stage II, stage III, or stage IV head&#xD;
      and neck cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the antiangiogenic effects of PEG-interferon alfa-2b, in terms of pre- and&#xD;
           post-treatment levels of microvessel density (MVD), endothelial cell apoptosis, vascular&#xD;
           endothelial growth factor (VEGF), interleukin-8, basic fibroblast growth factor (bFGF),&#xD;
           Nuclear Factor-KappaB (NF-KB), matrix metalloproteinase/MMP-9, and NF-KB in biopsy&#xD;
           specimens, from patients with resectable stage II-IV squamous cell carcinoma of the head&#xD;
           and neck.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the clinical response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled study. Patients are randomized to 1 of 4 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients undergo surgery within 3 weeks after randomization.&#xD;
&#xD;
        -  Arm II: Patients receive PEG-interferon alfa-2b subcutaneously on days 1, 8, and 15.&#xD;
&#xD;
        -  Arm III: Patients receive PEG-interferon alfa-2b as in arm II but at a higher dose.&#xD;
&#xD;
        -  Arm IV: Patients receive PEG-interferon alfa-2b as in arm II but at a higher dose than&#xD;
           in arm III.&#xD;
&#xD;
      In arms II, III, and IV, patients undergo surgery within 1 week after completion of&#xD;
      PEG-interferon alfa-2b.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 weeks following treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control (no treatment), conventional surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron 5.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-interferon alfa-2b</intervention_name>
    <description>Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.</description>
    <arm_group_label>PEG-Intron 0.5 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron 2.5 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron 5.0 mg/kg</arm_group_label>
    <other_name>SCH 54031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional surgery</intervention_name>
    <description>Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>PEG-Intron 0.5 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron 2.5 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron 5.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant therapy</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>PEG-Intron 0.5 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron 2.5 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron 5.0 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck&#xD;
&#xD;
               -  Stage II, III, or IV disease&#xD;
&#xD;
               -  One of the following primary tumor sites:&#xD;
&#xD;
                    -  Oral cavity&#xD;
&#xD;
                    -  Oropharynx&#xD;
&#xD;
                    -  Hypopharynx&#xD;
&#xD;
                    -  Larynx&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
               -  Scheduled to undergo surgery as primary treatment&#xD;
&#xD;
                    -  Distant metastases or a second primary tumor allowed provided tumor deemed&#xD;
                       resectable by the surgeon&#xD;
&#xD;
          -  No squamous cell carcinoma of the nasopharynx or skin&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  White Blood Cells (WBC) &gt; 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 150,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
               -  Transfusion and/or epoetin alfa support allowed provided it is given ≥ 1 week&#xD;
                  before study entry AND the patient is stable&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  serum glutamic pyruvic transaminase (SGPT) ≤ 5 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  No hemolytic anemia&#xD;
&#xD;
          -  No hemoglobinopathies (e.g., thalassemia)&#xD;
&#xD;
          -  No prior or current ascites&#xD;
&#xD;
          -  No bleeding varices&#xD;
&#xD;
          -  No other evidence of decompensated liver disease&#xD;
&#xD;
          -  No symptomatic ischemic heart disease&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No other uncontrolled heart condition&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
          -  No documented pulmonary hypertension&#xD;
&#xD;
          -  No other chronic pulmonary disease&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No immunologically mediated disease, including any of the following:&#xD;
&#xD;
               -  Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Idiopathic thrombocytopenia purpura&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Autoimmune hemolytic anemia&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Severe psoriasis&#xD;
&#xD;
          -  No Central Nervous System (CNS) trauma&#xD;
&#xD;
          -  No confusion or disorientation&#xD;
&#xD;
          -  No active seizure disorders requiring medication&#xD;
&#xD;
          -  No spontaneous encephalopathy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No pre-existing uncontrolled thyroid abnormality&#xD;
&#xD;
          -  No poorly controlled diabetes mellitus&#xD;
&#xD;
          -  No history of major psychiatric illness that would prelude giving informed consent&#xD;
&#xD;
          -  No nonmalignant systemic disease that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior surgery&#xD;
&#xD;
          -  No prior interferon&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hormonal antineoplastic therapy&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy S. Herbst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>October 29, 2012</last_update_submitted>
  <last_update_submitted_qc>October 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

